All In MedTech

Device Trial Radar · NCT01503476

Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance

RD-40 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance

Last checked: Nov 19, 2026Latest source record: Jul 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

170

Actual

Start

Feb 2012

Primary completion

Mar 2016

Study completion Mar 2016

Sponsor

Lead sponsor
Medtronic - MITGPublic (MDT)
Sponsor type
Industry
First posted
Jan 4, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study Hypothesis: This study is designed as an integral part of the development of new or improved features or components of the Bravo® pH Monitoring System and may serve verification and validation purposes The study population will include a group of healthy volunteers (Group A) and a group of symptomatic patients with known or suspected gastroesophageal reflux disease (Group B). Group A: Healthy volunteers will not undergo invasive procedure. These volunteers may be asked to carry the capsule and\\or Bravo Recorder. These procedures will serve to evaluate different technical matters such as human interface, ergonomic aspects and communication performances of the system Group B: Symptomatic patients will undergo invasive procedure, including Bravo capsule delivery, positioning and attachment. Confirmation of capsule attachment may be done by endoscopically. These procedures will serve to evaluate overall system performance in actual clinical setup, for instance: Bravo Recorder performance including communication quality, human interface and similar, ergonomics of delivery device, pH Capsule performance, etc. Subjects from both study groups as well as physician may be asked to provide feedback on the procedure and/or document their activities during the procedure.

Conditions

  • Gastro Esophageal Reflux Disease

Interventions

  • Bravo® pH Monitoring SystemDevice

    Bravo pH monitoring

  • Bravo® pH Monitoring SystemDevice

    Bravo pH monitoring

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of data samples transmitted by the capsule and successfully received by the receiver (e.g. percent of missed samples and percent of corrupted samples)Time frame: up to 96 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bikur Holim medical center

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.